EDMONTON, ALBERTA--(CCNMatthews - Aug. 11, 2005) - CV Technologies Inc. (CVT) (TSX VENTURE:CVQ - News) today launched CELL-fX® - a new scientifically proven natural therapeutic for bone and joint pain approved by Health Canada. Four CFL teams today announced that they'll be using it to treat player injuries this season.
 
CVT president, CEO & Chief Scientific Officer Dr. Jacqueline Shan says, "We are pleased that Health Canada has approved the medical claims for CELL-fX: 'relieves symptoms of bone and joint pain.' Some consumers are perhaps confused and certainly concerned about the serious side effects of some of the leading drugs used for joint pain - one of which was involved in the world's biggest drug recall. We feel that CELL-fX is a strong alternative which is completely safe and has no significant side effects and will potentially be of benefit to millions of Canadians who suffer from osteoarthritis."

Dr. Shan says, "CVT has always had a strong connection to the sporting world because of COLD-fX® so we're happy that the Argos, Eskimos, Stampeders and Lions have decided to use this new therapeutic developed by using our patented ChemBioPrint technology and has been subjected to the same rigorous scientific standards we've set for all our products."

Dr. Shan adds "CELL-fX helps relieve joint pain. Equally importantly it helps in the vital formation of connective tissues within the cartilage to repair and prevent further joint deterioration which should be of benefit to athletes who suffer a lot of injuries as well as millions of Canadians who suffer from arthritic pain."

Dr. Shan says, "We plan to conduct a clinical study with CELL-fX involving players on the four teams as part of CVT's ongoing program of scientific research of its natural health products."

CELL-fX is an extract of shark cartilage rich in chondroitin sulphate, a naturally occurring critical building block of cartilage. Deteriorating cartilage causes inflammation and prevents joints from moving smoothly, resulting in joint pain. A recent independent analysis of 7 controlled clinical trials involving 703 patients indicated that chondroitin sulphate relieved osteoarthritic pain symptoms by 50%.

Dr. Shan stressed that, "It's very important for 'shark cartilage derived products' to dissolve completely in order to provide the best benefit. CELL-fX is distinguished from other similar products because of our approach to quality control and our standardization process, by utilizing our proprietary ChemBioPrint technology. In addition, our process enables that CELL-fX has a friendly and biologically efficient delivery form. It is 100% soluble and contains no additives.

CELL-fX has an NPN number issued by the Health Canada. It will be sold initially at more than 850 Shopper's Drug Marts and then will be expanded to a number of the leading national retailers.

ABOUT CV TECHNOLOGIES INC.

CV Technologies was founded in 1992. It aims to become a global leader in the development and commercialization of evidence based, natural medicines for disease prevention and health maintenance. CVT's lead product - COLD-fX®, - the top selling cold remedy in Canada according to ACNielsen, strengthens the immune system and is widely used as a leading anti-cold, anti-flu, non-prescription treatment. COLD-fX's unique, patented, mechanism of action was developed and standardized according to the Company's ChemBioPrint (CBP) technology. The CBP process precisely identifies the chemical profile and biological activity of multi-active components in natural compounds. The CBP process provides a manufacturing protocol that ensures each batch of compound delivers verifiable and provable health benefits.

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian!
securities authorities.